4D Molecular Therapeutics Completes Enrollment Of Phase 2 Prism Clinical Trial For Intravitreal 4D-150 In Patients With Wet AMD And Reports Interim Safety And Tolerability Data
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics has completed the enrollment of 50 patients for its Phase 2 PRISM clinical trial for 4D-150, a treatment for Wet AMD. The enrollment was completed two quarters ahead of initial projections. No serious adverse events or deviations from the protocol were reported. Initial interim Phase 2 efficacy data is expected to be presented in H1 2024, and an update regarding Phase 3 pivotal trial plans is expected in Q1 2024.
July 17, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
4D Molecular Therapeutics' successful and ahead-of-schedule completion of patient enrollment for its Phase 2 PRISM trial for 4D-150 could potentially boost investor confidence. The absence of serious adverse events also bodes well for the company.
The successful and ahead-of-schedule completion of patient enrollment for the Phase 2 PRISM trial indicates efficient execution by 4D Molecular Therapeutics. The absence of serious adverse events so far suggests that the trial is proceeding smoothly, which could potentially boost investor confidence in the company and its product, 4D-150. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100